FGI-106

FGI-106
Legal status
Legal status	US: Investigational New Drug;
Identifiers
	IUPAC name N1,N7-bis[3-(dimethylamino)propyl]-3,9-dimethylquinolino[8,7-h]quinoline-1,7-diamine;
CAS Number	501081-38-5 ;
PubChem CID	432342;
ChemSpider	382357;
UNII	BRT994456W;
CompTox Dashboard (EPA)	DTXSID701028028 ;
Chemical and physical data
Formula	C28H38N6
Molar mass	458.654 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C)CCCNc(c2ccc14)cc(C)nc2c1ccc3c4nc(C)cc3NCCCN(C)C;
	InChI InChI=1S/C28H38N6/c1-19-17-25(29-13-7-15-33(3)4)23-11-10-22-21(27(23)31-19)9-12-24-26(18-20(2)32-28(22)24)30-14-8-16-34(5)6/h9-12,17-18H,7-8,13-16H2,1-6H3,(H,29,31)(H,30,32); Key:WJUPENLNVUCETH-UHFFFAOYSA-N;

FGI-106 is a broad-spectrum antiviral drug developed as a potential treatment for enveloped RNA viruses, in particular viral hemorrhagic fevers from the bunyavirus, flavivirus and filovirus families. It acts as an inhibitor which blocks viral entry into host cells. In animal tests FGI-106 shows both prophylactic and curative action against a range of deadly viruses for which few existing treatments are available, including the bunyaviruses hantavirus, Rift Valley fever virus and Crimean-Congo hemorrhagic fever virus, the flavivirus dengue virus, and the filoviruses Ebola virus and Marburg virus.^[1]^[2]^[3]^[4]^[5]